Embed Size (px)
Citation preview
The European Association of Pharmaceutical Full-line Wholesalers
Groupement International de la Répartition Pharmaceutique the vital link in healthcare
Rue de la Loi 26, Box 14 T +32 (0)2 777 99 77 E [email protected]
1040 Brussels, Belgium F +32 (0)2 770 36 01 W www.girp.eu
Working Documents for the GIRP Managing Board
Day 1: 23rd January 2014, 10:30 am – 12:30 pm, GIRP office, Brussels
MEETING DETAILS
Date 23rd January 2014
Time 10:30 am to 12:30 pm
City/Country Brussels/Belgium
Address
GIRP Office
Rue de la Loi 26, box 14 1040 Brussels
Belgium
Contact
Tel.: +32 2 777 99 77
Fax: +32 2 770 36 01 www.girp.eu
Email: [email protected]
TABLE OF CONTENT
Agenda Item 1: Agenda of the meeting .................................................................................................... 2
Agenda Item 2: Minutes of the last meeting.............................................................................................. 3
Agenda Item 3: Financial Status 2013 ...................................................................................................... 8
Agenda Item 3: List of GIRP sponsors in 2014 ........................................................................................ 11
Agenda Item 5: Medical devices legislation package – status of lobbying activities .................................... 12
Agenda Item 6: Outline of GIRP Working Groups .................................................................................... 17
Agenda Item 7: Business Programme Annual General Meeting 2014 in Vienna .......................................... 25
Agenda Item 8: Meeting overview .......................................................................................................... 28
Page 2
Agenda Item 1: Agenda of the meeting
Agenda of the GIRP Managing Board
23rd January 2014, 10:30 am – 12:30 pm, GIRP office Brussels
WHO AGENDA INFO INPUT DECISION KEY
RJ 1. Welcome and approval of the meeting agenda o o
RJ: René Jenny
MDP: Monika Derecque-Pois
RJ 2. Approval of the minutes of the last meeting o
ALL
3. Preparation of the Board meeting
a) Financial status 2013/2014
b) Status of sponsorship
o o o
MDP 4. Status European Stakeholder Model (ESM) o
MDP 5. Medical devices legislation package – status of lobbying activities o
RJ 6. Outline of GIRP Working Groups o
MDP 7. Business programme Annual General Meeting 2014 in Vienna o
ALL 8. Miscellaneous
LUNCH
Page 3
Agenda Item 2: Minutes of the last meeting
Page 4
Page 5
Page 6
Page 7
8
Agenda Item 3: Financial Status 2013
Financial Status 2013
G.I.R.P. AISBL
Budget Actual at % budget Projection at % budget Budget % budget
Euro 2013 31/12/2013 2013 31/12/2013 2013 2014 2013
Travel (Transport & Hotel) 75.000,00 84.519,93 113% 75.000,00 100% 75.000,00 100%
Congress 130.000,00 140.946,04 108% 144.000,00 111% 200.000,00 154%
Office supplies 7.500,00 9.928,01 132% 7.600,00 101% 8.000,00 107%
Website 12.000,00 12.481,00 104% 15.000,00 125% 10.000,00 83%
Telecom 15.000,00 14.826,30 99% 10.000,00 67% 12.000,00 80%
Post 6.000,00 5.951,79 99% 4.900,00 82% 6.000,00 100%
Fee President 55.350,00 58.544,76 106% 55.350,00 100% 56.750,00 103%
Girp Office Staff1 300.000,00 300.391,98 100% 300.000,00 100% 307.500,00 103%
Girp Director General 161.191,50 161.191,44 100% 161.191,50 100% 165.220,00 102%
Board 8.000,00 7.891,45 99% 7.500,00 94% 8.000,00 100%
Working Groups 18.000,00 30.966,93 172% 39.000,00 217% 18.000,00 100%
Managing Board 5.000,00 4.969,49 99% 5.000,00 100% 5.000,00 100%
Bookkeeping external 13.000,00 13.000,00 100% 13.000,00 100% 13.500,00 104%
Auditor + VAT + control 4.300,00 4.300,00 100% 4.300,00 100% 4.300,00 100%
Office Rent 52.000,00 57.342,83 110% 52.000,00 100% 54.000,00 104%
Membership IFPW 5.500,00 5.745,37 104% 5.745,37 104% 6.000,00 109%
Public Relations & Rest., Reception 70.000,00 85.728,42 122% 70.000,00 100% 70.000,00 100%
Publications 12.000,00 14.017,88 117% 15.000,00 125% 12.000,00 100%
Subscriptions 16.000,00 19.898,34 124% 16.000,00 100% 16.000,00 100%
Legal Advice 38.000,00 38.150,04 100% 38.000,00 100% 38.950,00 103%
9
Technical Equipment 9.000,00 10.298,72 114% 7.500,00 83% 9.000,00 100%
Study communication 0,00 0,00 0% 0,00 0% 0,00 0%
Leadership Forum / Regional Meeting 15.000,00 0,00 0% 3.000,00 20% 15.000,00 100%
Misc.tax&bank 3.000,00 2.864,88 95% 3.000,00 100% 3.000,00 100%
VAT not recoverable 0,00 0,00 0% 0,00 0% 0,00 0%
EXPENSES 1.030.841,50 1.083.955,60 105% 1.052.086,87 102% 1.113.220,00 108%
Contribution Full Members Associations 382.072,67 388.614,65 102% 389.323,82 102% 397.902,10 104%
Contribution Pan European Companies/Group (7) 446.951,25 450.833,52 101% 401.722,27 90% 356.319,47 80%
Contribution Associated Professional
Members 10.455,00 12.546,00 120% 12.546,00 120% 12.859,65 123%
Contribution Associated External Members /
Sponsors 195.000,00 215.000,00 110% 215.000,00 110% 215.000,00 110%
Other income (Events participation and sponsorship) 100.000,00 135.932,41 136% 127.774,38 128% 120.000,00 120%
Interest & other income 5.000,00 1.654,79 33% 4.500,00 90% 4.000,00 80%
REVENUES 1.139.478,92 1.204.581,37 106% 1.150.866,47 101% 1.106.081,22 97%
RESULT 108.637,42 120.625,77
98.779,60
-7.138,78
10
Status accounts on 31/12/2013 Status Business Account 12.371,57
Status Savings Account 305.434,90
Invoices and costs to be paid 31/12/2013 44.371,47
Belgian VAT to receive back =
53.161,41
1 Communication and Events Manager (Viktoria Keri) [FT –int.]; Membership and Corporate Affairs Manager (Anneliese Gattringer) [FT –int.]; Economic and European Affairs Manager (Magda Savin) [FT –int.]; Deputy Director General (Martin FitzGerald) [PT –ext. consult]; Office Manager (Mihai Rotaru) [PT -ext]; Communications officer (Emer Begley) [PT –ext. consult.]; Trainee (Ruth NicGinnea) [FT –int]; Trainee (Susanne Tischler) [FT –int]. Also ancillary costs included.
11
Agenda Item 3: List of GIRP sponsors in 2014
Company Country Company description
IMS Health USA IMS Health is the world’s leading information, services and technology company dedicated to making healthcare perform better.
Insight Health Germany Market research and health care research in the medical field
KNAPP Austria New technology to warehouse logistics
SSI Schäfer Austria Logistics system and software, storage and conveying
CAPPI France Designing, testing and manufacturing customized packaging solutions for temperature-sensitive and pharmaceutical products
IBS USA/Italy Pharmaceutical distribution software
SENSITECH Netherlands
Sensitech offers a wide range of services that include the ongoing collection, management, and storage of temperature-sensitive supply chain data, as well as the analysis and reporting required to translate data into actionable information.
12
Agenda Item 5: Medical devices legislation package – status of lobbying activities
GIRP Overview of National Lobbying Activities
Report on contacts – outcome of contacts with your country’s Council delegate/
representative
Name Ms Danielle Van Mulukom
Country Netherlands
Function Senior policy advisor
Address Ministry of Health
2500 EJ The Hague Netherlands
Email [email protected]
Telephone +31 70 3406542
Fax -
Contacted on 08/11/2013 & 22/11/2013
Outcome
On November 19 the Working Party has discussed article 12.
With regard to article 12.b there was less support to (partly) change the
wording. Despite earlier feedback that they would give full support to GIRPs position concerning Article 12 b, it seems member states highly emphazise the
importance of adequate information for users and patients. Distributors also have a responsibility in the chain in this respect. How to control and to secure
this in practice, can be solved in many ways. It is estimated that there will be little support to change this article.
At the meeting there was much support for the (German) proposal (largely in
line with the GIRP amendment) to skip article 12.c as whole.
As expected there has been no discussion about articles 13 & further.
Actions to be taken We keep each other informed
13
Name Dr. Matthias Neumann
Country Germany
Function Federal Ministry of Health (AIMDD, MDD, IVDMD Legislation)
Address
Bundesministerium für Gesundheit Referat 122 – Medizinproduktesicherheit
Friedrichstraße 108
10117 Berlin Tel +49 (030) 20640 – 2636
Email [email protected]
Contacted on ongoing
Outcome
PHAGRO is in contact with the German representative who is in charge of the Regulation. The Council will be drafting a paper including the positions of all
the Council members. The BMG is aware of PHAGRO’s position. In Germany, the issue of the registration procedure of medical devices is similar to the one
for medicinal products. It is currently strongly debated and the German health
insurance companies exercise a lot of pressure in this respect. Thus the BMG is more focused on other content issues than Article 12.
Actions to be taken
Name Mr. Gian Marco Currado
Country United Kingdom
Function Head Dep. EU & International Policy & Strategy, Medicines and Healthcare
products Regulatory Agency
Email [email protected]
Contacted on 15 November 2013
Outcome
The standpoint of the representative is that the wording of the Article 12 of the proposal for a regulation on medical devices is acceptable the way it is now
because he believes that it will be interpreted in such way that wholesalers
would only need to show that they are taking a proportionate approach to checking the packs.
Actions to be taken The British Association of Pharmaceutical Wholesalers will continue to discuss
with its national authorities.
14
Name Dr.
Dr.
Annamaria
Pietro
Donato
Calamea
Country Italy
Function
Head of Units, Ministry of Health, Department of Planning and Organisation of
the National Health Service - Directorate General of Medical Devices, pharmaceutical services and safety in healthcare
Email [email protected]
Contacted on
Outcome The person responsible of the MDD in Italy is currently taking the same view
as the UK.
Actions to be taken Mr. Scrofina from ADF will continue to discuss with the representatives to explain the implications of leaving the wording out for potential interpretation
rather than pressing for a concrete wording immediately.
Name Prof. Dr. Wolfgang Ecker
Country Austria
Function Bundesministerium für Gesundheit
Email [email protected]
Contacted on
Outcome
In Austria first informal contacts have taken place. The Austrian Council
representative has signalled that they may be willing to support GIRP’s position in the Council. Further discussions are planned to take place still before
Christmas.
The Austrian Chamber of Commerce has contacted Prof. Dr. Eckert on behalf of ARGE Pharmazeutika.
Actions to be taken
15
Name Ms. Carmen Abad
Country Spain
Function Agencia Espaňola de Medicamentos y Productos Sanitarios
Email [email protected]
Contacted on meeting on 20th December 2013
Outcome Ms. Abad believes that a wholesaler cannot be classified as a distributor and
therefore the provision does not apply to wholesalers
Actions to be taken
Name Ms. Emmanuelle Barsky
Country France
Function bureau dispositifs médicaux de la direction générale de la santé au ministère de la santé
Email [email protected]
Contacted on
Outcome
According to the French government, through the Medical Devices Bureau of
the Ministry of Health, article 12 does not pose any particular problems as the obligations on distributors exist in other economic sectors as well.
For example, in the toy industry, the same obligations exist for manufacturers and distributors. However, this does not mean that each toy box has to be
opened for verification. To this effect, the EC has published a guide for the
application of the directive:
http://ec.europa.eu/enterprise/sectors/toys/files/tsd-guidance/tsd_rev_1-
6_explanatory_guidance_document_en.pdf.
Despite our efforts to convince the French government of the particularities of
our sector, and their willingness to listen to our arguments, the fact that other
economic sectors have to abide to similar provisions will make it difficult to obtain any derogations.
Actions to be taken
16
Name Ms. Josiane Van der Elst
Country Belgium
Function Director General in the Directorate General Inspection, FAGG
Email [email protected]
Contacted on 12th December 2013
Outcome
The Belgian authorities have the same interpretation as GIRP, that according
to the current text, every pack would need to be opened. The Belgian
representatives believe that this burden on wholesalers would be completely out of proportion. Therefore the Belgian authorities assured that they will
reflect about the best way how to raise this point during the Council meeting.
Actions to be taken
17
Agenda Item 6: Outline of GIRP Working Groups
GIRP Working Groups’ Terms of Reference
Please note that the GIRP membership guidelines are applicable to all GIRP Committees, Councils and Project Groups. The guidelines were approved by the GIRP Managing Board and Board and should
serve to ensure continuity in the work of the working groups and provide guidance on subjects under
discussion. In particular, we would like to draw your attention to the tightened requirement of 50% minimum attendance of all meetings.
OK TO DISCUSS:
Technical issues relevant to the sector represented by the association
Publicly available information on market trends and general promotional opportunities
Industry public relations or advocacy activities
NOT OK TO DISCUSS:
Issues concerning price changes, pricing strategies, terms of sales, price mark-ups, discounts,
allowances, credit terms, etc. on a company level
Costs of distribution, cost accounting and methods of computing costs on a company level
Individual company figures on or plans as to sources of supply, inventories, sales, marketing and promotion
Any matters relating to individual suppliers or customers, including any attempted collective
action that might have the effect of excluding suppliers or customers from the market
Information as to future plans of individual companies concerning technology, investments
18
Name Technical Committee (TC)
Description
The main task of the Technical Committee is to raise the profile of pharmaceutical full-line wholesalers, from a quality point of view, towards the partners of the supply
chain and the authorities (national, international and European) as this will lead to an
advantageous market environment for full-line wholesalers. It also assists with the associations’ replies to consultation documents and analyses legislation with regard to
its impact on the operational aspects of pharmaceutical wholesalers’ business. The Technical Committee aims to provide, when possible, early warning about emerging
technical problem due to adherence to new obligations, rules and standards and
identify the pros and cons of proposed changes that can occur in the business. The Technical Committee furthermore assists in the drafting and reviewing of GIRP’s
position and advocacy papers from a technical viewpoint.
Work plan
Delegated Acts to complement the Falsified Medicines Directive
Implementation of the European Good Distribution Practice Guidelines
(2013/C 68/01)
Revision of European Medical Devices legislation and European Commission
recommendation on Unique Device Identification (UDI) for medical devices European Stakeholder Model – for a European Medicines Verification System
– technical issues
Cold chain and narcotic products storage and delivery
Following development in relation to regulatory aspects of the distribution of
active substances (APIs)
Membership1
Participation is open to the staff of any GIRP full member company/association with technical expertise. Participants should have a high level of expertise and knowledge
in the development of technical aspects of wholesaling (storage, pick-pack, etc.), as well as IT expertise.
Meetings Minimum twice per year
Chairmanship Rotating
1 for the current members, please see GIRP Working Group Members List
19
Name Legal Affairs Committee (LAC)
Description
The main task of the Legal Affairs Committee is to help raise the profile of
pharmaceutical full-line wholesalers, from a legal point of view, in the
associations position vis a vis the external environment – supply chain partners, health authorities and other relevant stakeholders.
The objective is to follow developments in the legislative and regulatory
domain with a primary focus on assessing the impact that legislative and regulatory proposals have on the business of pharmaceutical full-line
wholesalers.
The legal affairs committee is also charged with duties related to the
commenting on public consultation and preparing the position of GIRP in relation to legislative and regulatory proposals.
The legal affairs committee assists GIRP proposing suggested amendments
as the legislative and regulatory proposals pass through the respective institutions of the European decision making bodies.
The legal affairs committee is furthermore responsible for commenting from a
legal perspective positions on the development of GIRP advocacy papers,
statements and documents which form a critical aspect of the work of the association.
The legal affairs committee also follows health policy and healthcare system
legal framework developments in the different EU Member States. The legal affairs committee is responsible for preparing for the association all
duties related to legal aspects for the smooth operation of the association.
Work plan
The Delegated Acts to complement the Falsified Medicines Directive – follow
up actions. Follow and support with the implementation of the European Good
Distribution Practice Guidelines (2013/C 68/01).
Follow and support lobbying efforts of GIRP in relation to the revision of
European Medical Devices legislation and European Commission recommendation on Unique Device Identification (UDI) for medical devices.
European Stakeholder Model – for a European Medicines Verification System
– legal and political issues Other EU legislative and regulatory proposals – EU data protection,
transparency directive, general products safety directives, …
Membership2
Participation is open to the staff of any GIRP full member company/association with a legal background is preferable as well as in-depth knowledge of pharmaceutical law
and knowledge of competition law. Participants should have a high level of expertise
and knowledge in the development of legal aspects of full-line wholesaling.
Meetings Approximately 4 times per year
Chairmanship Rotating
2 for the current members, please refer to the Legal Affairs Committee - List of Active Members
20
Name Advisory Council Supply Chain Solutions (ACSCS)
Description
GIRP set up its Advisory Council Supply Chain Solutions in order to be able to discuss
and promote to the supply chain partners the diversified range of services that GIRP Members provide. This includes discussions about homecare services, specialty
products, pre-wholesaling etc.
Work plan
examine different ways of improving communication and increasing mutual
understanding with the pharmaceutical industry
examine issues such as for example collaborative forecasting for ordering and
replenishing screen possibilities for joint ordering platforms and defining standards for
data interchange
promote advanced shipping notifications and electronic invoices
revise the content and structure of the GIRP Wholesale Brief (for eventual
external use)/ to elaborate an external communication tool for the pharmaceutical industry
establish an information database on the range of wholesalers’ services and
to ascertain information on which members offers what kind of services improve the representation of wholesalers at manufacturer-oriented
conferences
conduct a fact-finding mission to obtain manufacturers’ needs and
requirements
keep the manufacturers’ services presentation updated with most recent
developments develop and keep the manufacturers database
Membership3
Participation in the council is open to the staff of any GIRP full member company and
involvement is actively encouraged especially from those companies that are developing manufacturer services. Participants should have a high level of expertise
and knowledge in the development of manufacturer services and have a clear vision and commitment to actively contribute to the work programme.
Meetings approx. 4 times per year
Chairmanship Mr. Thomas Ehmann
3 for the current members, please see GIRP Working Group Members List
21
Name Advisory Council Retail (ACR)
Description
The Advisory Council Retail aims to inform / support members with retail interests
about the pharmaceutical retail business, to discuss new developments which impact pharmacy retail and elaborate health care services which can be provided by retail
pharmacies in a cost effective manner.
Work plan
Revision and update of pharmacy chain ownership overview
Evaluation of the impact of EU health policy developments on retail
pharmacies, including: The Falsified Medicines Directive & Delegated Acts
Impact of the pharmacovigilance legislation EC initiative on active and healthy ageing and unding possibilities through
Horizon 2020 Discussion about retail specific results of GIRP IPF study
Mapping of product range and services by country
Membership4
Participation in the Advisory Council Retail is open to the staff of any GIRP full member company and involvement is actively encouraged especially from those
companies that are developing pharmacy and patients services through or supporting retail business. Participants should have a high level of expertise and knowledge in
the pharmaceutical retail market and the development of pharmacy services and have
a clear vision and commitment to actively contribute to the work programme.
Meetings approx. once per year
Chairmanship TBD
4 for the current members, please see GIRP Working Group Members List
22
Name Economic and Social Affairs Committee (ECOSOC)
Description
The Economic and Social Affairs Committee (ECOSOC) discusses cost segmentation of full-line wholesaling companies, pricing and reimbursement systems in Europe,
market developments on national and European level, remuneration systems for medicines distribution and the economic impact of political and legal measures on the
full-line wholesaling business.
Work plan
Analysis and revision of GIRP data:
o GIRP statistics o GIRP country reports
o GIRP margin overview Update on EU Health policy developments:
o Information on Delegated Act and current developments
o Developments regarding the European Medicines Verification System
o Medical devices regulatory framework updates Support for the Ariadne task force for countries in difficulty
Support and help for national associations to deal and negotiate with local
authorities
Evaluation of the different types of wholesale remuneration systems
Possible EU funding opportunities for studies on the wholesale business and
pharmaceutical sector
Membership5
Participation is open to the staff of any GIRP full member company/association with sound economic expertise. Participants should have a high level of expertise and
knowledge in the development of economic aspects of the wholesale business and of
the pharmaceutical market in general.
Meetings Twice per year
Chairmanship Mr. René Jenny
5 for the current members, please see GIRP Working Group Members List
23
The GIRP Project Groups were set up following a decision of the GIRP Board that, as a guiding
principle, GIRP should accommodate all business interests of its members, including special business interest shared by a cluster of companies.
Name Patient Compliance and Homecare Project Group (PCH)
Description
The Patient Compliance and Homecare Project Group is dedicated to enhancing collaboration among a cluster of GIRP member companies which provide services in
the areas of patient compliance and homecare. The main objective of this project
group is to identify, create and/or participate in projects of mutual benefit to the members of the group and make these services known to the European institutions
and other stakeholder organisations as well as to social insurance organisations. The point of reference for any projects undertaken by this group should be the benefit of
patients.
Work plan
Participation in the European Innovation Partnership on Active and Healthy
Ageing action A1 Prescription and adherence to medical plans Update and revision of the compilation of GIRP presentation on ‘Patient
Compliance and Homecare Services’ Update of the mapping exercise Patient Compliance & Homecare
Develop a formula for quickly mobilising the group of members to participate
in and / or lead key initiatives launched by public authorities, or other
stakeholders
Consider ethnic issues in connection with the delivery of services in the field Approach manufacturers and patient groups to make them aware of the
possibilities
Contact the healthcare authorities and different categories of payers, such as
insurance companies in order to promote the services offered by GIRP
members Continue the collection of evidence on the positive impact of patient
compliance and homecare services on healthcare costs and the wide-ranging
benefits that arise from increased patient compliance Discuss pharmacovigilance issues and subjects such as safety and quality in
homecare
Membership6
Participation is open to the staff of any GIRP full member company/association that runs or is involved in patient compliance and/or homecare programmes. Participants
should have a high level of expertise and knowledge in the field of patient compliance and/or homecare services. All members should have a clear vision and commitment
to actively contribute to the work programme.
Meetings Twice per year
Chairmanship TBD
6 for the current members, please see GIRP Working Group Members List
24
Name eHealth Project Group
Description
The main objective of this project group is to identify, create and/or participate in eHealth and mHealth projects of mutual benefit to the members of the group and to
exchange best practice information with a view to setting highest standards for the sector overall.
Work plan
Update on activities on EU level:
o European Innovation Partnership Active and Healthy Ageing
o Commission eHealth stakeholder group
o 2nd eHealth Action Plan Update of the mapping the sector (eHealth services offered by members)
Monitor the upcoming European Commission Green Paper on mHealth, due
for publication in early 2014
Contact different stakeholders active in the eHealth and mHealth sectors in
order to cross-share experiences Discuss subjects such as electronic interaction and decision support systems
Membership7
Participation is open to the staff of any GIRP full member company/association that runs or offers eHealth services. Participants should have a high level of expertise and
knowledge in the field of eHealth and/or mHealth and/or ICT services. All members should have a clear vision and commitment to actively contribute to the work
programme.
Meetings Twice per year
Chairmanship TBD
7 for the current members, please see GIRP Working Group Members List
25
Agenda Item 7: Business Programme Annual General Meeting 2014 in Vienna
Draft Conference Programme
GIRP 55th Annual General Meeting 2
nd – 3
rd June 2014, Vienna, Austria
Conference Day I, 2nd June 2014
Opening
Mr. René Jenny, President, GIRP
Welcome address by the Austrian Association of Pharmaceutical Wholesalers ARGE Pharmazeutika
Dr. Andreas Windischbauer, President of ARGE Pharmazeutika, Managing Director Herba Chemosan
Keynote address
Mr. Alois Stöger, Minister of Health, Austria
Keynote addresses
Fostering an innovative agenda in healthcare Mr. Tonio Borg, European Commissioner for Health and Consumer Policy, European Commission
Megatrends in healthcare Mr. Per Båtelson, Chairman of the Board, Karolinska University hospital, Stockholm
Coffee break
Partnerships in the Austrian medicines supply chain
Panellists:
Dr. Andreas Windischbauer, President of ARGE Pharmazeutika, Managing Director, Herba Chemosan
Mag. Max Wellan, President of the Austrian Chamber of Pharmacists
Dr. Robin Rumler, President of Austrian Pharmaceutical Industry Association (Pharmig), Managing Director of Pfizer Austria
Challenges and opportunities from the perspective of society and medicines Dr. Christa Wirthumer-Hoche, Head of the Austrian Medicines Agency (AGES) TBI
Lunch break
26
eHealth – a strategic investment in healthcare access for patients anytime, anywhere Mr. Thomas Hendrik Ilves, President, Estonia TBC
How eHealth can improve the quality and safety of healthcare for patients
Keynote address
Mr. Paul Timmers, Director, Directorate H Sustainable & Secure Society, DG CONNECT, European Commission TBC
Developing and adapting mHealth programmes across Europe Mr. Eduardo Pisani, Director General, IFPMA
Session chairperson: TBD
Panellists:
Mr. Pierre Chancel, Head of Sanofi Diabetes, Sanofi TBI
Ms. Emely Kelly, Celesio (MyMed) TBC
Mr. Štefan Krchňák, President PGEU TBI
Dr. Clemens Martin Auer, Austrian Ministry of Health, Director Section 1 Health Systems and Coordination TBC
Coffee break
Securing medicines access by advancing Public Service Obligations Session chairperson: TBD
Keynote address
Mr. Daniel Bahr, former Health Minister Germany TBI
Panellists:
Dr. Isabelle Adenot, President, Conseil National de l'Ordre des Pharmaciens
Representative of Belgian Government TBI
Ms. Josiane Van der Elst, Director General in the Directorate General Inspection, FAGG TBC
27
Conference Day II, 3rd of June 2014
European and international trends in the wholesale sector (IMS session)
Mr. Per Troein, Vice President Strategic Alliances, IMS Health
Mr. Doug Long, Vice President, Industry Relations IMS Health
Coffee break
Building an innovative supply chain in an era of uncertainty – working together Session chairperson: Dr. Roger Sorel, Board Member, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
Panellists:
Mr. Stephan Borchert, Member of the Board, Celesio AG
Mr. Wolfgang Mähr, Regional Director, Alliance Healthcare
Mr. Aleksandr Kraytser, Head Channel Management Region Europe, Novartis Pharma AG
Mr. John Chave, Secretary General, Pharmaceutical Group of the European Union (PGEU)
Mr. Nick Haggar, Head of Western Europe, Middle-East & Africa, Sandoz, President, EGA TBC
Mr. Dipankar Bhattacharjee, President and Chief Executive Officer Generics Europe, Teva Pharmaceuticals Europe B.V
How innovative partnerships in the EU foster patients access to cancer drugs. A model for other therapeutic areas?
Dr. Andreas Penk, President Oncology Europe, Country Manager Germany, Pfizer
Closing address
Ms. Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
Farewell lunch
Post-conference workshop: European Stakeholder Model progress update TBC
Mr. Richard Bergström, Director General, European Federation of Pharmaceutical, Industries and Associations (EFPIA)
Mr. John Chave, Secretary General, Pharmaceutical Group of the European Union (PGEU)
Dr. Heinz Kobelt, Secretary General, European Association of Euro Pharmaceutical Companies (EAEPC)
Ms. Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
Mr. Adrian van den Hoven, Director General, European Generics Association (EGA)
28
Agenda Item 8: Meeting overview
Type Meeting Date Time Location
Managing Board
Managing Board (MB members only) 01 June 2014 10 am - 12 pm Palais Hansen Kempinski Vienna, Austria
Managing Board (MB members only) 12 November 2014 tbc Brussels
Managing Board (MB members only) 07 June 2015 10 am – 12 pm Belgrade, Serbia
Board
Board (Board members only) 01 June 2014 2 pm - 4 pm Palais Hansen Kempinski Vienna, Austria
Board (Board members only) 12 November 2014 tbc Brussels
Board (Board members only) 07 June 2015 2 pm – 4 pm Belgrade, Serbia
Working Groups/Project Groups
Advisory Council Supply Chain Solutions tbc tbc tbc
Advisory Council Retail tbc tbc tbc
Technical Committee 5 March 2014 10 am - 1 pm GIRP office, Brussels
Legal Affairs Committee 12 March 2014 12 pm - 2 pm GIRP office, Brussels
Economic and Social Affairs Committee 5 February 2014 10 am - 4 pm GIRP office, Brussels
eHealth and Patient Compliance and Homecare tbc tbc tbc
Annual General Meeting 2014, Vienna
Managing Board (MB members only) 01 June 2014 10 am – 12 pm Palais Hansen Kempinski Vienna, Austria
Board (Board members only) 01 June 2014 2 pm – 4 pm Palais Hansen Kempinski Vienna, Austria
EU Health Policy Briefing (full members only) 01 June 2014 4 pm – 5 pm Palais Hansen Kempinski Vienna, Austria
Annual General Assembly 01 June 2014 5 pm – 6 pm Palais Hansen Kempinski Vienna, Austria
Welcome Dinner 01 June 2014 8 pm onwards Heuriger Mayer am Pfarrplatz, Vienna, Austria
Annual Conference Day 1 02 June 2014 9 am – 5 pm Palais Hansen Kempinski Vienna, Austria
Gala Dinner 02 June 2014 8 pm onwards Palais Liechtenstein, Vienna, Austria
Annual Conference Day 2 03 June 2014 10 am – 1 pm Palais Hansen Kempinski Vienna, Austria
Farewell Lunch 03 June 2014 1 pm onwards Palais Hansen Kempinski Vienna, Austria
Autumn Meeting 2014
Managing Board (MB members only) 12 November 2014 tbc Brussels
Board (Board members only) 12 November 2014 tbc Brussels
EU Health Policy Briefing (full members only) 12 November 2014 tbc Brussels
Autumn General Assembly 12 November 2014 tbc Brussels
GIRP & IMS Dinner 12 November 2014 tbc Brussels
Autumn Conference 13 November 2014 tbc Brussels
EP Lunch Reception 13 November 2014 12:30 pm - 3 pm European Parliament, Brussels
Annual General Meeting 2015, Belgrade
Managing Board (MB members only) 07 June 2015 10 am – 12 pm Belgrade, Serbia
Board (Board members only) 07 June 2015 2 pm – 4 pm Belgrade, Serbia
EU Health Policy Briefing (full members only) 07 June 2015 4 pm – 5 pm Belgrade, Serbia
Annual General Assembly 07 June 2015 5 pm – 6 pm Belgrade, Serbia
Welcome Dinner 07 June 2015 8 pm onwards Belgrade, Serbia
Annual Conference Day 1 08 June 2015 9 am – 5 pm Belgrade, Serbia
Gala Dinner 08 June 2015 8 pm onwards Belgrade, Serbia
Annual Conference Day 2 09 June 2015 10 am – 1 pm Belgrade, Serbia
Farewell Lunch 09 June 2015 1 pm onwards Belgrade, Serbia
Managing Board and Board Meeting Strategy Review Meeting tbc tbc Brussels
Directors of national Associations meeting Directors of national Associations meeting tbc tbc Berlin
Regional Meeting Regional Meeting tbc tbc tbc
